Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
Phase 4
- Conditions
- Arthritis, RheumatoidSpondylitis, Ankylosing
- Interventions
- Registration Number
- NCT01072058
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers
- Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers
Read More
Exclusion Criteria
- Clinical heart failure
- Chagas'disease
- Stable or unstable angina
- Past history of myocardial infarct
- Systemic árterial hypertension (grade 3)
- Valvulopathy
- Chronic kidney disease
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TNF blockers TNF blockers (infliximab, adalimumab, etanercept) -
- Primary Outcome Measures
Name Time Method Development, deterioration ou improvement of subclinical heart dysfunction 0, 6 ,12, 18 and 24 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de são PAulo
🇧🇷Sao Paulo, Brazil